CTSO · Cytosorbents Corp
Substantial doubt about the company's ability to continue as a going concern.
“approximately $4.4 million in unrestricted cash and cash equivalents and $1.5 million of non-current restricted cash which may not be sufficient to fund the Company's operations beyond the next twelve months from the issuance of these condensed consolidated financial statements. These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Sep 8, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Sep 8, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTSO
this stock
Cytosorbents Corp
|
$21.52M | — | +48.5% | — | 3.4% |
|
ABT
Abbott Laboratories
|
$188.69B | -16.0% | +5.7% | 30.3 | 1.2% |
|
MDT
Medtronic plc
|
$118.41B | -4.3% | +8.4% | 22.8 | 1.1% |
|
SYK
Stryker Corp
|
$116.27B | -21.6% | +11.2% | 31.4 | 1.8% |
|
BSX
Boston Scientific Corp
|
$66.11B | -52.8% | +12.5% | 18.5 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Sep 8, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTSO | — | — | — | — | — |
| SPY | +0.1% | -1.1% | +15.3% | -0.6% | +11.8% |
| vs SPY | — | — | — | — | — |